Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL9279245 | 0.92 | CA12 (0.35) | CA12CA1CA2CA9TSHR | |
| SCHEMBL18596895 | 0.76 | — | — | |
| SCHEMBL22143239 | 0.74 | CA12 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL972108 | 0.70 | — | — | |
| SCHEMBL6151834 | 0.70 | CA12 (0.40) | CA12CA1CA2CA9TSHR | |
| SCHEMBL1071106 | 0.69 | — | — | |
| SCHEMBL15639670 | 0.69 | TSHR (0.35) | TSHR | |
| SCHEMBL1707076 | 0.69 | TSHR (0.46) | CA12CA1CA2CA9TSHR | |
| SCHEMBL6031323 | 0.67 | TSHR (0.42) | CA12CA1CA2CA9TSHR | |
| Hydrochloric Acid SCHEMBL2688962 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836075-A | Preparation method of oseltamivir phosphate catalyzed by azide-free palladium-free catalyst | 华东理工大学 | 2023-10-03 | — | — | CN | claimed |
| WO-2022167637-A1 | PROCESS FOR MODIFYING AN AROMATIC POLYETHER BACKBONE AND A MODIFIED POLYETHER OBTAINED BY THIS PROCESS | Technische Universität Berlin (DE) | 2022-08-11 | — | — | WO | disclosed |
| WO-2020244483-A1 | SAPONIN CONJUGATE AND VACCINE OR PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | LIANG PI HUI (CN) | 2020-12-10 | — | — | WO | disclosed |
| WO-2011162562-A2 | [6+5] FUSED BICYCLES AS A THROMBIN ANTAGONIST, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE BICYCLES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-12-29 | — | — | WO | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| WO-1995009857-A1 | O-ARYL, O-ALKYL, O-ALKENYL AND O-ALKYNYL-MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5250678-A | For autoimmune, infectious diseases, organ transplant rejection; skin diseases, antiinflammatory agents | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5208228-A | Skin disorders | MERCK & CO., INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530888-A1 | Fluoromacrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-03-10 | — | — | EP | disclosed |
| US-5189042-A | Treating autoimmune diseases, preventing transplant rejection | MERCK & CO. INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0515071-A2 | O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | CA2, CACNA1A, CACNA1C | CA12 283/4885CA1 36/4885CA2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.